Intravenous tissue plasminogen activator thrombolysis in patients without major arterial occlusion seems to be safe and effective

European Neurology

Volumn 64, Issue 5, 2010, Pages 258-264

  Kimura, Kazumi ^a   Iguchi, Yasuyuki ^a   Shibazaki, Kensaku ^a   Sakamoto, Yuki ^a   Watanabe, Masao ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Magnetic resonance angiography; Tissue plasminogen activator; Tissue plasminogen activator infusions, outcome

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; STROKE;

AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; BLOOD PRESSURE; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENTRICULAR; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77957758167     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320950     Document Type: Article

References (18)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute isch-emic stroke. N Engl J Med 1995; 333:1581-1587.
2. Delgado-Mederos R, Rovira A, Alvarez-Sa-bin J, Ribo M, Munuera J, Rubiera M, San-tamarina E, Maisterra O, Delgado P, Mon-taner J, Molina CA: Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke. Stroke 2007; 38: 955-960.
3. Kim YS, Garami Z, Mikulik R, Molina CA, Alexandrov AV: Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 2005; 36:869-871.
4. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabin J: Improving the predictive accuracy of recanali-zation on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004; 35: 151-156 . (Pubitemid 38057610)
5. Mori E, Minematsu K, Nakagawara J, Yama-guchi T, Sasaki M, Hirano T: Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41:461-465.
6. Rubiera M, Alvarez-Sabin J, Ribo M, Mon-taner J, Santamarina E, Arenillas JF, Huertas R, Delgado P, Purroy F, Molina CA: Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanaliza-tion in acute ischemic stroke. Stroke 2005; 36: 14 52-1456.
7. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA: Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000; 283:1145-1150.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Ku m mer R, Wa h lg ren N, Ton i D : T h rombol -ysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
9. Hacke W, Kaste M, Fieschi C, Toni D, Lesaf-fre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plas-minogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
10. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Teje-dor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
11. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, S o i n ne L, Ton i D, Va n ho oren G : T h romb o l y-sis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOSt): an observational study. Lancet 2007; 369:275-282.
12. Yamaguchi T, Mori E, Minematsu K, Nak-agawara J, Hashi K, Saito I, Shinohara Y: Al-teplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Tria l (J-ACT). Stroke 2006; 37: 1810-1815.
13. The NINDS t-PA Stroke Study Group: Intra-cerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-2118.
14. Lansberg MG, Thijs VN, Bammer R, Kemp S, Wijman CA, Marks MP, Albers GW: Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38:2275-2278.
15. Barber PA, Hill MD, Eliasziw M, Demchuk AM, Pexman JH, Hudon ME, Tomanek A, Frayne R, Buchan AM: Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 2005; 76:1528-1533.
16. Demchuk AM, Felburg RA, Alexandrov AV: Clinical recovery from acute ischemic stroke after early reperfusion of the brain with intravenous thrombolysis. N Engl J Med 1999; 340:894-895.
17. Caplan LR: Intracranial branch atheroma-tous disease: a neglected, understudied, and underused concept. Neurology 1989; 39: 1246-1250.
18. Furst G, Saleh A, Wenserski F, Malms J, Coh-nen M, Aulich A, Neumann-Haefelin T, Schroeter M, Steinmetz H, Sitzer M: Reliability and validity of noninvasive imaging of internal carotid artery pseudo-occlusion. Stroke 1999; 30: 1444-1449.